Breast Cancer, Colon Cancer, Lung Cancer, Non-Small Cell, Prostate Cancer, Rectum Cancer
Conditions
Keywords
Clinical validation, AI model solutions, experimental dedicated-platform
Brief summary
The goal of this observational study is to see how useful an experimental viewer and AI solutions are for clinicians in their daily work. The investigators want to find out if the AI helps clinicians interpret medical images for different types of cancer. The AI solutions aim to: * Classify whether prostate cancer is low or high risk * Classify the histological subtype in breast cancer * Estimate the life expectancy of patients with lung cancer * Determine the size of colon cancer, lymph node involvement and the possibility of metastasis.. * Assess the invasion of sorrounding tissues in the case of rectum cancer. The study will involve clinicians from various centres who will review a set of cases not previously analysed by the AI. Clinicians will do this in two phases: first using only their own expertise and then with the help of the AI solutions. The technical team want to see if the AI solutions assist clinicians and could become useful in the everyday clinical practice. Clinicians will complete a survey to share their feedback on the usability of the platform and how helpful the AI solutions are.
Detailed description
In order to conduct a robust clinical validation, the investigators have designed a study on the required sample size. The study is design to evaluate the role of an AI-assisted tool as a support for improving the daily clinical work. The investigators used an online website (https://statulator.com/SampleSize/ss2PP.html) for the calculation and use the paired binary proportions option. Using the case of prostate cancer, the investigators want to compare the probability of correct risk classification in prostate cancer by clinicians alone and/or guided by AI. The study will have a significance (α) = 0.05; power (β) = 80%; the analysis will be two sided and with equal group sizes. An 10% improvement in cancer risk classification was observed when clinicians had access to an AI tool solution (Yilmaz et al.,). In addition, the authors reported that expert readers had an accuracy rate of 81% compared to 69% for novice readers when determining the Gleason score of lesions (a medical term used in pathology to classify the aggressiveness of cells in a tumour). The authors also assumed an 80% correlation between paired observations. As a result, at least 60 new cases would be needed to evaluate the performance of the AI tool.
Interventions
OTHERRisk in prostate cancer
the prediction involves the classification of the prostate cancer according to the level of prostatic antigen (PSA), the biopsy classification of the aggressiveness of the tumour, and also the localisation of the tumour
OTHERLife expectancy in lung cancer
Clinicians will evaluate life expectancy in lung cancer using CTs, together with some clinical information.
OTHERHistological subtype
An assessment by pathology of the subtype of breast tumour
OTHERStaging of colon cancer
classify size, lymph node involvement and possibility of metastasis in medical images (computerized tomosynthesis) of thorax and pelvis region
OTHERinvasion in rectum cancer
assess whether vascular extramural o mesorectal fascia has been invaded in the tumour using magnetic resonance medical images taken at diagnosis in the pelvic region
Sponsors
University of Pisa
University Hospital Rijeka
University of Messina
Istanbul Medipol University Hospital
Centro Hospitalar do Porto
Hospitales Universitarios Virgen del Rocío
IRCCS Policlinico S. Donato
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Charite University, Berlin, Germany
Osakidetza
Le Collège des Enseignants de Radiologie de France
Instituto de Investigacion Sanitaria La Fe
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* patients with an histological confirmation of cancer diagnosis (prostate, lung, breast, colon or rectum) * availability of radiological images (MR for prostate and rectum, CT for lung and colon or mammographys for breast). * enough follow up (12 months for prostate, breast and rectum), 18 months for lung, and 24 months for colon.
Exclusion criteria
* patients with incomplete or low quality data (radiological, pathological or uncomplete clinical data necessary for the ground truth)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Usability of experimental viewer with AI tools | 5 months | Usability of the platform was assessed at the end of each of the two study phases: a standard clinical phase (without artificial intelligence assistance) and a second phase assisted by AI models. Participants evaluated their experience using a 5-point Likert scale, where 1 indicated strongly disagree and 5 indicated strongly agree, in response to statements regarding ease of use, interface clarity, system efficiency, overall satisfaction, and other aspects related to user interaction with the platform. This assessment enabled a comparison of user perceptions of the viewer's usability under both conventional clinical conditions and AI-assisted conditions. Higher scores reflect a better user experience. |
| Utility of experimental medical images viewer | 5 months | The utility of the experimental viewer was assessed by comparing clinicians' diagnostic accuracy and time spent when using the system alone versus with AI assistance. Higher accuracy and reduced interpretation time were considered indicators of greater utility. The goal was to determine whether the viewer enhances clinical decision-making, streamlines workflows, and supports better patient care. Additional data such as clinician gender, specialty, and experience were collected to enable subgroup analyses. Statistical evaluations included confusion matrices to assess diagnostic performance, and Sankey flow diagrams to visualize changes in decision-making between unaided and AI-assisted phases. These tools provided a comprehensive understanding of the viewer's practical benefit in real clinical scenarios. |
Countries
Spain
Outcome results
None listed